Study of HS-10365 for RET fusion-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced or metastatic non-small cell lung cancer that has spread or cannot be removed by surgery.
- Your tumor must test positive for a RET fusion using a central lab.
- You must have at least one tumor that can be measured on scans.
- You must be able to take care of yourself (ECOG score 0 or 1).
- You cannot have had prior treatment with a selective RET inhibitor or multi-kinase inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, SNH-118110, for people with advanced solid tumors that have a specific genetic change called RET. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called HS-10370 given along with other anticancer treatments for advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if this combination is safe and effective for people who have run out of standard options.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This Phase 1/2 trial tests HS-10375, a study drug, in people with advanced or metastatic non-small-cell lung cancer (NSCLC) whose cancer has a specific EGFR mutation (C797S). It may help by targeting that mutation when standard treatments are not an option.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
Hear when a new Nonsmall Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.